APO Research
Talk to an analyst

APO RESEARCH · REPORT

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast 2026-2032

29 December 2025191 pages

Choose your research edition.

Industry ResearchIrritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, projected growth trends, production technology, application and end-user industry.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Company

Allergan

Amneal Pharms

Astellas Pharmaceuticals

Bausch Health

Sebela Pharmaceuticals

Pharscin Pharma

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type

XIFAXAN

Lotronex

Viberzi

Other

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application

Hospitals Pharmacy

Retail Pharmacy

Other

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. XIFAXAN Major Manufacturers Table 3. Lotronex Major Manufacturers Table 4. Viberzi Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals Pharmacy Major Manufacturers Table 8. Retail Pharmacy Major Manufacturers Table 9. Other Major Manufacturers Table 10. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends Table 11. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers Table 12. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges Table 13. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Pcs) Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2026) & (K Pcs) Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2027-2032) & (K Pcs) Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2021-2026) Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2027-2032) Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers, Product Type & Application Table 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type 2021 VS 2025 VS 2032 (K Pcs) Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K Pcs) Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027-2032) & (K Pcs) Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021-2026) Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2027-2032) Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2026) & (US$/Pcs) Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2027-2032) & (US$/Pcs) Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application 2021 VS 2025 VS 2032 (K Pcs) Table 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K Pcs) Table 54. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2027-2032) & (K Pcs) Table 55. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2021-2026) Table 56. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2027-2032) Table 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2026) & (US$/Pcs) Table 58. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2027-2032) & (US$/Pcs) Table 59. Allergan Company Information Table 60. Allergan Business Overview Table 61. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 62. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 63. Allergan Recent Development Table 64. Amneal Pharms Company Information Table 65. Amneal Pharms Business Overview Table 66. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 67. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 68. Amneal Pharms Recent Development Table 69. Astellas Pharmaceuticals Company Information Table 70. Astellas Pharmaceuticals Business Overview Table 71. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 72. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 73. Astellas Pharmaceuticals Recent Development Table 74. Bausch Health Company Information Table 75. Bausch Health Business Overview Table 76. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 77. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 78. Bausch Health Recent Development Table 79. Sebela Pharmaceuticals Company Information Table 80. Sebela Pharmaceuticals Business Overview Table 81. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 82. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 83. Sebela Pharmaceuticals Recent Development Table 84. Pharscin Pharma Company Information Table 85. Pharscin Pharma Business Overview Table 86. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 87. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 88. Pharscin Pharma Recent Development Table 89. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 90. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 91. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K Pcs) Table 92. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027-2032) & (K Pcs) Table 93. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 94. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 95. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 96. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 97. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K Pcs) Table 98. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2027-2032) & (K Pcs) Table 99. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 100. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 101. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 103. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 104. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Pcs) Table 105. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 106. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 107. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 108. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 109. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 110. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 111. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K Pcs) Table 114. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027-2032) & (K Pcs) Table 115. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 116. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 117. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K Pcs) Table 120. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2027-2032) & (K Pcs) Table 121. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 122. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 123. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 125. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 126. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Pcs) Table 127. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 128. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 129. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 130. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 131. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 132. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 133. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 134. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 135. Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 136. Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 137. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 138. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 139. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K Pcs) Table 140. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027-2032) & (K Pcs) Table 141. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 142. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 143. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 144. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 145. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K Pcs) Table 146. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2027-2032) & (K Pcs) Table 147. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 148. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 149. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 150. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 151. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K Pcs) Table 152. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027-2032) & (K Pcs) Table 153. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 154. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 155. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K Pcs) Table 158. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2027-2032) & (K Pcs) Table 159. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 160. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 161. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Pcs) Table 165. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 166. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 167. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 168. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 169. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 170. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 171. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 172. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 173. China Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 174. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 175. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 176. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 177. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K Pcs) Table 178. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027-2032) & (K Pcs) Table 179. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 180. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 181. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 182. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 183. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K Pcs) Table 184. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2027-2032) & (K Pcs) Table 185. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 186. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 187. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 188. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 189. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 190. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Pcs) Table 191. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 192. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 193. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 194. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 195. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 196. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 197. Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 198. Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 199. Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 200. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 201. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 202. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 203. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 204. Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 205. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List Table 209. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Image Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. XIFAXAN Image Figure 5. Lotronex Image Figure 6. Viberzi Image Figure 7. Other Image Figure 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals Pharmacy Image Figure 11. Retail Pharmacy Image Figure 12. Other Image Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2021-2032) & (K Pcs) Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2021-2032) & (K Pcs) Figure 22. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2021-2032) & (K Pcs) Figure 23. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2021-2032) & (K Pcs) Figure 24. Asia (Excluding China) Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2021-2032) & (K Pcs) Figure 25. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2021-2032) & (K Pcs) Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2021-2032) Figure 42. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2021-2032) Figure 43. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Application (2021-2032) Figure 44. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2021-2032) Figure 45. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2021-2032) Figure 46. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2021-2032) Figure 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2021-2032) Figure 49. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2021-2032) Figure 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2021-2032) Figure 53. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2021-2032) Figure 54. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2021-2032) Figure 55. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Application (2021-2032) Figure 56. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2021-2032) Figure 57. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2021-2032) Figure 59. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2021-2032) Figure 61. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2021-2032) Figure 69. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • XIFAXAN
  • Lotronex
  • Viberzi
  • Other
Applications
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Other
Companies covered
  • Allergan
  • Amneal Pharms
  • Astellas Pharmaceuticals
  • Bausch Health
  • Sebela Pharmaceuticals
  • Pharscin Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
  3. 1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 XIFAXAN
  5. 1.2.3 Lotronex
  6. 1.2.4 Viberzi
  7. 1.2.5 Other
  8. 1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
  9. 1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals Pharmacy
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
  1. 2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
  2. 2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
  3. 2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
  4. 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
  3. 3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
  9. 3.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers
  2. 4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers
  6. 4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market CR5 and HHI
  16. 4.8.2 2025 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Tier 1, Tier 2, and Tier 3
5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
  1. 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type
  2. 5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
  6. 5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032) & (K Pcs)
  8. 5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type
6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
  1. 6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
  2. 6.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application
  6. 6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032) & (K Pcs)
  8. 6.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 Amneal Pharms
  8. 7.2.1 Amneal Pharms Company Information
  9. 7.2.2 Amneal Pharms Business Overview
  10. 7.2.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  12. 7.2.5 Amneal Pharms Recent Developments
  13. 7.3 Astellas Pharmaceuticals
  14. 7.3.1 Astellas Pharmaceuticals Company Information
  15. 7.3.2 Astellas Pharmaceuticals Business Overview
  16. 7.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  18. 7.3.5 Astellas Pharmaceuticals Recent Developments
  19. 7.4 Bausch Health
  20. 7.4.1 Bausch Health Company Information
  21. 7.4.2 Bausch Health Business Overview
  22. 7.4.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  24. 7.4.5 Bausch Health Recent Developments
  25. 7.5 Sebela Pharmaceuticals
  26. 7.5.1 Sebela Pharmaceuticals Company Information
  27. 7.5.2 Sebela Pharmaceuticals Business Overview
  28. 7.5.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  30. 7.5.5 Sebela Pharmaceuticals Recent Developments
  31. 7.6 Pharscin Pharma
  32. 7.6.1 Pharscin Pharma Company Information
  33. 7.6.2 Pharscin Pharma Business Overview
  34. 7.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  36. 7.6.5 Pharscin Pharma Recent Developments
8 North America
  1. 8.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
  2. 8.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2032)
  5. 8.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
  6. 8.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2032)
  9. 8.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
  10. 8.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
  2. 9.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2032)
  5. 9.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
  6. 9.2.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2032)
  9. 9.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
  10. 9.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
  2. 10.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2032)
  5. 10.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
  6. 10.2.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
  2. 11.1.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2032)
  5. 11.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
  6. 11.2.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2032)
  9. 11.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
  10. 11.3.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
  2. 12.1.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
  6. 12.2.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
  10. 12.3.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis
  2. 13.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
  6. 13.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
  9. 13.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst